ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / NRC / options
OABI (44) MXCT (34) ABSI (44) ONMD (26) ⌘ Pro Terminal →

NRC Health (NRC) Options Positioning, Max Pain & Unusual Sweeps

$23.83 +1.45% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $23.85

NRC Health (NRC) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $527.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NRC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NRC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, NRC Health (NASDAQ: NRC) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $23.83 (+1.45% 1D, market cap $527.1M). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, NRC ranks #108 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NRC compare to OABI and MXCT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), NRC carries a Roarable C+ (67/100 RQD), trailing P/E of 44.8x, gross margin of —, and ROIC of 21.0%. By comparison, OABI (OmniAb Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -22.6%, cap $742.9M) and MXCT (MaxCyte Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -27.1%, cap $164.1M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NRC?
▼

Per NRC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000070487), NRC Health generated $137.4M in revenue (-4.0% YoY), $11.6M in net income, and $15.7M in free cash flow against $134.9M in total assets and $75.0M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $23.85 (+0.07%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 18/20 (A) • 11.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 67/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.6% avg 90D alpha vs SPY • 56.4% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C+
025507510067
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk D+
Cash (18)Whales (15)SEC (12)Macro (10)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE+4.1% Base Target
$29 Bull$25 Base$19 Bear
📬 FREE NRC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NRC)Realized 20D OHLCV Swing Band: ±8.2%
Deterministic 5-Pillar Attribution (67/100 Composite)
🔍 WHY NRC SCORES 67/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+18/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 11.5% FCF Margin ($15.7M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+15/20 pts (22% of score)

20D Institutional Volume Accumulation (±8.2% realized swing band)

▼ #1 Drag / Risk Factor: Macro Regime Fit10/20 pts (-10 pt drag)

Macro rate sensitivity & RSI-14 (65.3) create a -10 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
59
Grade C$20.17+2.6% Next Q
Q2 (-2Q)
62
Grade C+$20.69+5.1% Next Q
Q3 (-1Q)
64
Grade C+$21.75+9.6% Next Q
Current
67
Grade C+$23.83+1.6% Hist 90D α
Trajectory: C (59) → C+ (67)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the NRC Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 67/100 (C+) score, NRC faces multiple-compression risk if 44.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Priced at 45x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($21.28) or 200D SMA ($19.19) invalidates the momentum regime and cuts Target Base ($24.80) toward Bear Floor ($19.34).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NRC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NRC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 67%NO 33%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±8.2%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (NRC)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for NRC.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating NRC & AI Leaders Without Chasing Tops

  • ✓Institutional whale strikes & implied earnings move audit on NRC
  • ✓How disciplined traders manage risk using pre-published trigger & invalidation levels
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NRC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +30.79%▲ ASCENDING CHANNEL
2026-11-03O $23.49H $23.83L $23.49C $23.83VOL 86.2K
RES: $24.48SUP: $19.98SMA50: $21.28SMA200: $19.19
$25.00$22.51$20.03$17.54$15.06RES $24.48SUP $19.98$23.832026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NRC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NRC Butterfly Map → + Track NRC →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
33.4%/yr Implied 5Y Growth

vs. -4.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NRC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NRC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NRC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NRC)

Health Care Rank #108 of 1015 ⚔️ OABI vs NRC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NRC vs. OABI, MXCT, ABSI, ONMD)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, NRC Health (NRC) ranks #108 by composite RQD confidence (67/100, grade C+) and #430 by equity capitalization ($527.1M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. NRC currently leads its immediate peer cohort in composite quantitative strength at 67/100 (C+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NRC ACTIVE
NRC Health
C+ 67/100 44.8x — 21.0% +1.45% $527.1M Benchmark Subject
OABI
OmniAb Inc.
D 44/100 — — -22.6% -2.29% $742.9M /oabi-vs-nrc →
MXCT
MaxCyte Inc.
E 34/100 — 96.0% -27.1% -8.09% $164.1M /mxct-vs-nrc →
ABSI
Absci Corporation
D 44/100 — — -35.0% -8.02% $1.91B /absi-vs-nrc →
ONMD
OneMedNet Corp (Class A)
E 26/100 — -30.0% -35.0% -3.43% $25.4M /onmd-vs-nrc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000070487 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), NRC Health (NRC) reported GAAP revenue of $137.4M (-4.0% vs. FY2024 revenue of $143.1M , and -7.5% cumulative change since FY2023) , GAAP net income of $11.6M, operating cash flow of $26.4M, and free cash flow of $15.7M (-17.9% YoY). On the balance sheet, NRC closed FY2025 with $134.9M in total assets against $75.0M in total debt (Altman Z-Score: 3.82, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $137.4M $11.6M $26.4M $15.7M $134.9M $75.0M
FY2024 (FY) 2024-12-31 $143.1M $24.8M $34.6M $19.2M $132.5M $57.9M
FY2023 (FY) 2023-12-31 $148.6M $31.0M $38.1M $38.1M — —

3. NRC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NRC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, NRC Health (NASDAQ: NRC) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $23.83 (+1.45% 1D, market cap $527.1M). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, NRC ranks #108 in composite RQD confidence.

How does NRC compare to OABI and MXCT in the Health Care sector?

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), NRC carries a Roarable C+ (67/100 RQD), trailing P/E of 44.8x, gross margin of —, and ROIC of 21.0%. By comparison, OABI (OmniAb Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -22.6%, cap $742.9M) and MXCT (MaxCyte Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -27.1%, cap $164.1M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NRC?

Per NRC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000070487), NRC Health generated $137.4M in revenue (-4.0% YoY), $11.6M in net income, and $15.7M in free cash flow against $134.9M in total assets and $75.0M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NRC trading relative to its 50-day, 200-day, and 52-week technical levels?

NRC last traded at $23.83 (+1.45% on volume of 86,230 shares), positioning the stock +11.98% above its 50-day simple moving average ($21.28) and +24.18% above its 200-day simple moving average ($19.19). Across its 52-week range of $11.73 to $24.40, NRC sits at the 95.5% percentile with a 14-day RSI of 65.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.2% ($21.88 to $25.78).

Direct Sub-Reports: NRC RQD Cockpit NRC 12M Forecast NRC Earnings & Move NRC Dividends & DRIP NRC Insiders & 13F NRC Whale Options NRC Profit Sankey NRC News & Why
ROARABLE RATING BRIEF • RQD 67/100 (C+) ✓ SEC XBRL & RQD VERIFIED

NRC — NRC Health: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

NRC Health (NRC) earns a live Roarable RQD composite score of 67/100, corresponding to a C+ letter grade (Roarable Hold) at a spot price of $23.83 (+1.45% 1D, market capitalization $527.1M).

  • Fundamental Cash Engine (18/20): Anchored by return on invested capital (ROIC) of 21.0%, gross margin of —, operating margin of 16.4%, and free cash flow yield of 3.03%.
  • Whale 13F & Options Flow (15/20) + Insider Conviction (12/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (12/20): Incorporates a 1.00x equity beta, Altman Z-Score of 3.82, Piotroski F-Score of 4/9, and Debt/Equity of 5.36x.

2. Business Model, Unit Margins & SEC Financial Trajectory

NRC Health is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Commercial Physical & Biological Research industry.4M for FY 2025, indicating a revenue base of that scale in the most recent reported period. The company operates with a market capitalization that the profile describes as $0.5B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), NRC Health (NRC) reported $137.4M in annual revenue (up from $143.1M in FY2024, -4.0% YoY) and $11.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($148.6M revenue, $31.0M net income) through FY2025, NRC scaled operating cash flow to $26.4M and free cash flow to $15.7M, backed by $134.9M in total assets against $75.0M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C+ • RQD 67/100): Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 18/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $11.73 – $24.40 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 44.8x trailing P/E and 18.6x EV/EBITDA against 16.4% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies: — Sector correlations beyond the stated beta of 1.0: — Second-order bottlenecks: — A prospective investor should watch for disclosure of supplier, customer, or partner concentration in future filings, since none is captured here.

  • Key Question #1: Can NRC sustain or expand its 16.4% operating margin and 21.0% ROIC against Biotechnology: Commercial Physical & Biological Resarch peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $137.4M and free cash flow of $15.7M, how will capital allocation balance growth reinvestment against $75.0M in total debt?
  • Key Question #3: How sensitive is NRC's 41.7x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NRC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for NRC Health (NRC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NRC Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NRC Bull vs. Bear Conversation Board — What's Your Call at $23.83?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NRC 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NRC:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $31.46 (+32.0%)
📌 Pinned Debate

Per the RQD rating, a 21% ROIC and 3.03% FCF yield back an upper-neutral score with a watch-for-breakout posture.

Long NRC at $23.83 targeting $31.46. Per the RQD rating, a 21% ROIC and 3.03% FCF yield back an upper-neutral score with a watch-for-breakout posture.. Institutional whale score is 15/20 and the risk/reward vs. the $11.73 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader 🐂 BULL

@RedlineAuditor Shorting a 15/20 institutional whale-flow stock at $23.83 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $18.83 (-21.0%)
Spot @ $23.83

Revenue and net income declined each year from FY 2023 to FY 2025 while debt rose to $75.0M against $4.1M of cash.

Fading this rally in NRC at $23.83. Revenue and net income declined each year from FY 2023 to FY 2025 while debt rose to $75.0M against $4.1M of cash.. With a beta of 1.0 and the stock sitting at $23.83 (52-wk range $11.73–$24.40), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%